J3465
J3465 – Injection, voriconazole, 10 mg · NDC Crosswalk & Billing Units
HCPCS Level II J-code · Medicare Part B drug billing
J-code
● 11 NDCs crosswalked per 10 MG $0.563/unit ASP+6%
📋 J3465 summary
J3465 is a HCPCS Level II J-code used to bill voriconazole, 10 mg, billed per 10 MG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.
Brand names associated with J3465: Vfend Iv*, Vfend, Voriconazole
Code J3465
Billing unit 10 MG Payment limit $0.563/unit NDC-Crosswalk 11
Quarter Q3 2026
RxCUI Atlas Trace the drug concept →
⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.
🗂️ Key billing facts
HCPCS codeJ3465
DescriptorInjection, voriconazole, 10 mg
Billing unit10 MG
Payment limit / unit$0.563
Est. ASP / unit$0.531 est.
Mapped NDCs11
Data periodQ3 2026
Last updated2026-08-20
💊 About Voriconazole DRUG GUIDE
Voriconazole treats several serious fungal infections.
Across all available forms — tablets, oral suspension, and intravenous (IV) injection — it is used for invasive aspergillosis (a dangerous mold infection), candidemia (Candida fungus in the bloodstream) in patients who are not neutropenic (not severely low on white blood cells), other deep-tissue Candida infections, and serious infections caused by Scedosporium apiospermum or Fusarium species in patients who cannot tolerate or have not responded to other antifungal treatments.Esophageal candidiasis (a Candida infection of the esophagus, the swallowing tube) is also an approved use for most formulations.
Note on the oral tablet form (generic voriconazole tablets): that specific tablet formulation is approved for patients aged 12 to 14 years weighing at least 50 kg, and all patients 15 years and older — not for younger or smaller children.
The oral suspension and the IV injection are approved for patients 2 years and older for most of these conditions.
Clinical overview from our editorial drug guide for Voriconazole. For billing reference, see the sections above.
🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026
📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$0.563
Est. ASP / unit
$0.531 est.
Est. after 2% sequester
$0.552
HCPCS dosage
10 MG
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.
Full HCPCS code details (official CMS record)
Long descriptionInjection, voriconazole, 10 mg
CoverageD — Special coverage instructions apply
Pricing indicator51 — Drug — priced under the ASP methodology
Type of service1 — Medical care
BETOS-2O1E
ASC payment group—
Action codeN — No maintenance this year
Effective date2019-01-01
Date added2004-01-01
Source: CMS HCPCS Level II code file (imported via admin).
🧮 Dosing & billing-units calculator HCPCS UNITS
One billing unit of J3465 = 10 mg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.
🔁 NDCs that bill under J3465 WITH EST. MEDICARE PAY
11 NDCs map to J3465. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($0.563/unit) × that package's bill units.
| NDC (11-digit) | Drug | Labeler | Package | Strength | Bill units | Est. pay / pkg | NADAC / unit | Status | Source |
|---|---|---|---|---|---|---|---|---|---|
| 00049-3190-01 | VFEND Voriconazole 10 mg/mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Roerig | 1 VIAL, SINGLE-USE in 1 CARTON (0049-3190-... | 10 mg/mL | 20 | $11.26 | — | ● Active | CMS ASP |
| 00049-3190-28 | VFEND Voriconazole 10 mg/mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Roerig | 1 VIAL, SINGLE-DOSE in 1 CARTON (0049-3190... | 10 mg/mL | 20 | $11.26 | — | ● Active | CMS + PDAC |
| 00049-4190-01 | VFEND VORICONAZOLE 10 mg/mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Roerig | 1 VIAL, SINGLE-USE in 1 CARTON (0049-4190-... | 10 mg/mL | 20 | $11.26 | — | ● Active | CMS ASP |
| 00781-3416-94 | Voriconazole 10 mg/mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Sandoz | 1 VIAL, SINGLE-USE in 1 CARTON (0781-3416-... | 10 mg/mL | 20 | $11.26 | — | ● Active | CMS ASP |
| 65219-0190-30 | Voriconazole 10 mg/mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Fresenius | 1 VIAL, SINGLE-DOSE in 1 CARTON (65219-190... | 10 mg/mL | 20 | $11.26 | — | ● Active | CMS + PDAC |
| 70436-0029-80 | voriconazole 200 mg/1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Slate | 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLU... | 200 mg/1 | 20 | $11.26 | — | ● Active | CMS + PDAC |
| 70594-0067-01 | Voriconazole 10 mg/mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Xellia | 1 VIAL, SINGLE-DOSE in 1 CARTON (70594-067... | 10 mg/mL | 20 | $11.26 | — | ● Active | CMS + PDAC |
| 71288-0027-30 | Voriconazole 10 mg/mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Meitheal | 1 VIAL, SINGLE-DOSE in 1 CARTON (71288-027... | 10 mg/mL | 20 | $11.26 | — | ● Active | CMS + PDAC |
| 72266-0131-01 | Voriconazole 10 mg/mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Fosun | 1 VIAL, SINGLE-DOSE in 1 CARTON (72266-131... | 10 mg/mL | 20 | $11.26 | — | ● Active | CMS + PDAC |
| 72572-0875-01 | Voriconazole 10 mg/mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Civica, | 1 VIAL, SINGLE-USE in 1 CARTON (72572-875-... | 10 mg/mL | 20 | $11.26 | — | ● Active | CMS + PDAC |
| 31722-0224-31 | Voriconazole 10 mg/mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Camber | 1 VIAL, SINGLE-DOSE in 1 CARTON (31722-224... | 10 mg/mL | 20 | $11.26 | — | ● Active | PDAC |
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.
📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)
Period
Total Part B spend
$119.85
Claims
28
Beneficiaries
12
Spend / beneficiary
$9.99
Spend / claim
$4.28
Trend by period
Where J3465 ranks among Part B drugs · 2026 (Q1) · neighbors ±5
Total spending — #811 of 824
#806
DILTIAZEM HCL-0.9% N... J1163
$166.44
#807
ADRENALIN(J0165)* J0165
$164.81
#808
PROGESTERONE J2675
$144.09
#809
LIDOCAINE HCL IN 5%... J2002
$140.95
#810
EPINEPHRINE J0166
$125.51
#811
VFEND IV* J3465
$119.85
#812
HALOPERIDOL LACTATE J1630
$88.45
#813
CLINDAMYCIN-0.9% NAC... J0737
$73.78
#814
CEFAZOLIN SODIUM(J06... J0688
$69.34
#815
HEPARIN SODIUM J1643
$64.49
#816
DIMENHYDRINATE J1240
$52.85
Total claims — #750 of 824
#745
HYPERRHO* J2790
29
#746
ZIEXTENZO Q5120
29
#747
HYPERHEP B* 90371
28
#748
SPEVIGO J1747
28
#749
TIGECYCLINE* J3243
28
#750
VFEND IV* J3465
28
#751
VALRUBICIN* J9357
28
#752
PALISADE DM MATRIX P... Q4350
28
#753
RECOMBIVAX HB 90743
27
#754
MORPHINE SULFATE(J22... J2272
27
#755
FIBRYGA J7177
27
Top Medicare Part B drugs by the selected metric. Click any drug to open its J-code page. Source: CMS Medicare Quarterly Part B Spending by Drug.
Full breakdown by period (2)
| Period | Total spend | Beneficiaries | Claims | $/beneficiary | $/claim |
|---|---|---|---|---|---|
| 2026 (Q1) | $119.85 | 12 | 28 | $9.99 | $4.28 |
| 2025 (Q1-Q4) | $4.3K | 64 | 341 | $66.90 | $12.56 |
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.
📈 Medicare Part B claims detail CMS PSPS · 2024
Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$4.5K
Medicare paid
$3.5K
Submitted services
30,864
Denial rate
83.4%
Allowed / service
$0.87
Submitted charges
$175.3K
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.
🗺️ Where J3465 is utilized
⏳
The geographic utilization map is building for this code — it aggregates millions of CMS Part B claim lines, then caches the result. Refresh in a moment; if it doesn’t appear, this code may have no reportable Part B utilization.
📊 What bills under J3465
J-codes are billing codes often used for drugs billed under the medical benefit. This connects the billing code to the NDC package records it covers, by ingredient and labeler.
NDC products by ingredient
NDC products by labeler
🗃️ Data sources & freshness
Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Loaded
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk + DMEPDAC (PDAC)
11 NDCs mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Not available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2026
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.
⚠️ Practical billing caveats
- A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
- Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
- Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
- Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
- The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
- Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.
❓ J3465 billing FAQ
What is HCPCS code J3465?
J3465 is a HCPCS Level II J-code used to bill Injection, voriconazole, 10 mg under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J3465?
One unit of J3465 represents 10 MG. Report the number of units equal to the dose administered divided by 10 MG.
How many units of J3465 should I bill?
Divide the dose administered by the code's unit size (10 MG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J3465?
The Medicare Part B payment limit is $0.563 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $0.552 per unit. Payment limits are revised quarterly.
Which NDCs bill under J3465?
11 NDCs currently map to J3465 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J3465 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.